Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Patients randomized to the non Videx enteric coated (ddl EC)+lamivudine (3TC)+efavirenz (EFV) arm would continue their baseline nucleoside reverse transcriptase inhibitors (NRTIs) on study.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Documented HIV infection
≥ 18 years of age and weight at least 40kg
Two plasma HIV RNA levels \< 50 copies/mL during the qualification and screening period
Patients receiving a PI and ≥ 2 NRTIs
You may not be if
Pregnancy or breastfeeding
Documented virologic failure while on their first PI-based antiretroviral (ARV) regimen
Active AIDS-defining opportunistic infection or disease
Proven or suspected acute hepatitis within 30 days prior to study entry
Clareo Health | Study Switching HIV-1 Infected Patients With an Undetectable Viral Load on a First Protease Inhibitor-Based Regimen to an Efavirenz-Based Regimen
